EPI-506

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

EPI-506 (developed by Essa Pharma) is an experimental compound in phase I/II development for prostate cancer.[1] It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor. This mechanism of action is believed to allow the drug to block signaling from the androgen receptor and its splice variants.[2][3]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=EPI-506&oldid=718344267"